Gov. Glenn Youngkin announced a landmark partnership Friday with AstraZeneca, Lilly and Merck to create the nation’s largest ...

Merck & Company (($MRK)) has held its Q3 earnings call. Read on for the main highlights of the call. Merck & Co. Reports Positive Earnings Call ...

AstraZeneca, Eli Lilly and Merck committed $120 million to develop an advanced pharmaceutical manufacturing training center in Central Virginia.

The study will test the antibody-drug conjugate in combination with Keytruda in patients with HER2-overexpressing metastatic non-small cell lung cancer.

Shares of Danish rival Novo Nordisk slipped after it sought to snatch Pfizer target Metsera from the American drug giant's arms. Novo launched an unsolicited bid valued at up to $9 billion for obesity ...

The drugmaker issued the recall voluntarily after determining higher-than-acceptable levels may be present in some products.

Compared to its lackluster second quarter performance, Merck rallied somewhat in the third quarter of 2025. Revenue and ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision on Thursday, in part clarifying its ...

The Federal Circuit upheld a tribunal decision invalidating a Merck & Co. unit’s patent of a multiple sclerosis drug, ...

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...